Work

Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.

Year: 2008

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.1943.1943

Authors: Bing Z. Carter, Duncan H. Mak, Stephen Morris, Gautam Borthakur, Elihu Estey, Anna L. Byrd, Marina Konopleva, Hagop M. Kantarjian, Michael Andreeff

Institutions: The University of Texas MD Anderson Cancer Center, Aegera Therapeutics (Canada), University of Washington

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2556922330

FWCI: 0.862

Cites:

Cited by: 4

Related to: 10